Epi-GERD Study: Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease (GERD)

Launched by SCANDINAVIA PHARMA · Sep 17, 2019

Keywords

ClinConnect Summary

OBJECTIVE: To carry out an evaluation about the persistence and / or relapse of symptoms in Colombian patients with diagnosis of GERD.

MATERIALS AND METHODS: A multicentric cross-sectional epidemiological study will be carried out in Colombian patients with diagnosis of GERD and with current treatment or with a history of recent treatment with some PPI (Proton Pump Inhibitor). The persistence and / or relapse of symptoms will be evaluated as the main variable. The secondary variables to be evaluated include: Demographical analysis, treatment (s) used by patients, adverse events associated ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Previous diagnosis of Gastroesophageal Reflux Disease (GERD)
• • CURRENT treatment with a proton-pump inhibitor (PPI), OR NOT CURRENT treatment with some PPI but YES in the last year
• Exclusion Criteria:
• • Refusal to participate in the study by the patient.
• • Patients who, in the judgment of the Investigator, do not understand or are not willing to adequately answer to the questions.
• • Mental or psychiatric illness that, in the judgment of the investigator, does not allow adequate information to be obtained.